The Thailand Department of Disease Control has confirmed 6 new Mpox cases in 2026 as of May 19, reinforcing that the virus remains an active health concern in the country. The cumulative toll since July 2022 now stands at 1,074 confirmed infections and 16 deaths, with 97% of all patients being working-age men who report sexual contact with unfamiliar partners.
The Ongoing Challenge
Thailand continues to grapple with persistent Mpox transmission nearly four years into the outbreak. Recent cases underscore the virus's ability to exploit specific behavioral pathways, particularly within sexual networks and during crowded social gatherings in tourist areas.
Why This Matters
• Clade 1b expansion: 18 cumulative cases of the more transmissible strain detected since 2024, with 6 reported this year alone.
• Geographic concentration: Bangkok accounts for 458 cases—the highest burden—followed by Chon Buri, Phuket, Nonthaburi, and Samut Prakan.
• Traveler risk: Recent cases include a foreign tourist infected through sexual contact in a tourist area, flagged via International Health Regulations channels.
• Treatment access: Antiviral Tecovirimat (TPOXX) available for severe cases; vaccination on self-pay basis for high-risk groups since May 2026.
Persistent Transmission Patterns
Between April 26 and May 9, health authorities identified two fresh Clade 1b infections—both Thai men aged 25–40. One contracted the virus through sexual contact with a stranger; the other through prolonged close physical contact in a crowded tourist area during a festival. The same two-week window saw an additional case in a foreign visitor under similar circumstances.
These incidents underscore the twin transmission channels driving the epidemic: sexual networks among men who have sex with men (MSM), and high-density social settings during festive events. The Clade 1b strain, which first appeared in Thailand in 2024, has proven harder to contain than the older Clade II variant. While no Clade 1b cases have resulted in death, its enhanced transmissibility has prompted intensified surveillance protocols across tourist provinces.
Who Is Getting Infected
The demographic profile remains stark. Nearly all Mpox patients in Thailand are male, with the virus disproportionately affecting working-age men between 18 and 39. Health officials attribute this to behavioral risk factors rather than biological susceptibility: a significant share of patients report sexual encounters with strangers, often in entertainment districts or tourist zones.
Bangkok's 458 confirmed cases dwarf other regions, though popular destinations like Phuket and Chon Buri also register elevated counts. The capital's concentration reflects both higher population density and its role as a regional hub for nightlife and hospitality. A post-holiday surge in May saw 48 new infections, including 5 Clade 1b cases, suggesting seasonal travel patterns amplify transmission.
One fatality recorded in February 2026 involved a 44-year-old male inmate with multiple comorbidities, including HIV and hepatitis. This case highlights the particular vulnerability of immunocompromised individuals, for whom Mpox can escalate from mild skin lesions to life-threatening complications.
What Surveillance Looks Like Now
The Thailand Department of Disease Control has instructed public health agencies to prioritize screening in tourist areas and high-risk venues, including nightlife establishments and festival sites. Hospitals under the Bangkok Metropolitan Administration have been equipped to rapidly isolate suspected cases in negative pressure rooms, which remain mandatory for confirmed patients.
Epidemiological investigations now focus on contact tracing within sexual networks, a sensitive but essential component of outbreak response. Authorities have also stepped up outreach campaigns targeting MSM communities, integrating Mpox education with HIV and sexually transmitted infection prevention messaging. The goal is to normalize early symptom reporting—fever, rash, pustules—without stigmatizing affected groups.
International Health Regulations channels now flag imported cases, a measure that became critical after the foreign tourist infection in May. Cross-border coordination helps identify chains of transmission that might otherwise go undetected until secondary cases emerge.
What Residents Should Do: If you suspect exposure or develop symptoms (fever, swollen lymph nodes, or unexplained skin lesions), contact your local hospital or call the Department of Disease Control hotline for confidential guidance. Early reporting helps prevent onward transmission and ensures you receive appropriate care. Residents in high-risk groups can inquire about self-paid vaccination services at major hospitals in Bangkok, Phuket, Chon Buri, and other affected provinces.
Treatment and Vaccination Reality
Most Mpox infections resolve with supportive care: rest, pain management, and wound hygiene. For patients with severe symptoms or immunodeficiency, Tecovirimat (TPOXX) serves as the primary antiviral intervention. Thai hospitals maintain stocks, though demand remains modest given the relatively low severity of most cases.
Vaccination strategy in Thailand follows a targeted rather than universal model. The MVA-BN vaccine, received through ASEAN support, prioritized healthcare workers and individuals with higher sexual-risk behaviors. As of January 16, 2026, 2,175 doses from 2,220 vials had been distributed across Bangkok, Chon Buri, Chiang Mai, and Phuket.
Since May, JYNNEOS vaccination services have become available on a self-pay basis for high-risk groups, including gay, bisexual, and MSM populations. Post-exposure vaccination is also recommended for close contacts of confirmed cases. Mass vaccination for the general public is not on the table: risk to non-exposed individuals remains negligible, and supply constraints make universal coverage impractical.
Impact on Residents and Travelers
For foreign residents and expatriates, the Mpox situation requires situational awareness rather than panic. The virus does not spread casually through shared public spaces or brief encounters. However, individuals engaging in sexual activity with new or unfamiliar partners—particularly in nightlife or festival settings—should take precautions: consistent condom use, avoiding partners with visible rashes or lesions, and monitoring for symptoms in the weeks following potential exposure.
Travelers visiting tourist provinces should note that Bangkok, Phuket, Chon Buri, Nonthaburi, and Samut Prakan account for the bulk of cases. While casual tourism poses minimal risk, participation in crowded festive events or nightlife circuits increases exposure probability. Anyone developing fever, swollen lymph nodes, or unexplained skin lesions should seek medical attention promptly and disclose recent contact history.
For long-term residents in high-risk groups, self-paid vaccination offers protection. The two-dose regimen is recommended for individuals with multiple sexual partners or those frequently attending venues where transmission has been documented. Healthcare workers and laboratory staff handling specimens remain eligible for employer-funded doses.
The Path Forward
Thailand's Mpox response has matured since the first case in July 2022, yet the virus continues to exploit specific behavioral pathways. The emergence of Clade 1b adds complexity, requiring sustained vigilance even as case counts remain relatively low. Public health officials emphasize that avoiding close physical contact with symptomatic individuals and practicing safer sex remain the most effective prevention measures.
The disease control apparatus—surveillance networks, treatment protocols, targeted vaccination—functions well. The challenge lies in reaching populations most at risk with timely information and destigmatized access to prevention tools. For residents navigating daily life in Thailand, the Mpox threat remains real but manageable, contingent on informed choices and early medical engagement when symptoms arise.
